Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice.
- Author:
Kai-lin XU
1
;
Jian-ping JU
;
Xiu-ying PAN
;
Bing DU
;
Zhen-yu LI
;
Qun-xian LU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Bone Marrow Transplantation; immunology; methods; Combined Modality Therapy; Female; Graft vs Host Disease; prevention & control; Graft vs Leukemia Effect; Leukemia, Experimental; therapy; Leukemia, Lymphoid; therapy; Lymphocyte Transfusion; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Transplantation Conditioning; methods; Transplantation, Heterologous
- From: Chinese Journal of Hematology 2003;24(7):372-375
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish strategies for preventing graft versus host disease (GVHD) and reducing treatment associated morbidity while preserving graft versus leukemia (GVL) effect in nonmyeloablative allogeneic bone marrow transplantation (allo-BMT), with or without donor lymphocyte infusion (DLI) after BMT.
METHODS3 x 10(7) bone marrow cells mixed with 1 x 10(7) spleen cells from the same BALB/c mouse were transplanted into the nonablative irradiated inbred 615 mouse which received a single subcutaneous injection of 1 x 10(6) L615 leukemia cells three days before. The experiments were designed as follows (ten mice in each group): myeloablative BMT control group (group A), nonmyeloablative conditioning without BMT group (group B), nonmyeloablative BMT group (group C), and nonmyeloablative BMT + DLI group (group D). GVL effects were assessed by survival time, white blood cell count and L615 cells in peripheral blood and histologic changes. GVHD was assessed by signs of weight loss, ruffled fur, diarrhea and histologic changes of skin, liver and small intestines. Chimerism was detected by cytogenetic analysis and PCR technique.
RESULTSThe survival time of group A, B, C and D was (20.3 +/- 13.4), (15.9 +/- 1.1), (21.6 +/- 1.7) and (37.8 +/- 2.0) days, respectively, being no significant difference between group A and group C (P > 0.05). The survival time of group C was longer than that of group B (P < 0.01). And among group B, C and D, group D had the longest survival time (P < 0.01). GVHD signs and histologic changes were observed in 60% of control group mice at + 14 day, but none of group C and group D. 40% of mice in group A died of treatment associated morbidity within two weeks, but none in group C and group D. Allogeneic chimerism was kept in group A, but excluded gradually in group C.
CONCLUSIONGVL effect seems preserved in nonmyeloablative BMT mice, but weaker than that in myeloablative BMT mice. GVL effect seems to be enhanced by DLI after nonmyeloablative BMT. GVHD and transplantation associated morbidity seems to be reduced in nonmyeloablative BMT.
